New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

Ania M. Jastreboff; Robert F. Kushner

doi:10.1146/annurev-med-043021-014919

New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

Ania M. Jastreboff, Robert F. Kushner

Medicine, Endocrinology Division

Research output: Contribution to journal › Review article › peer-review

46 Scopus citations

Abstract

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of nascent hormone-based obesity therapeutics. With the understanding of the neurobiology of obesity rapidly expanding, these emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 RAs herald a new era of targeted, mechanism-based treatment of obesity. This article reviews GLP-1 RAs in the treatment of obesity and previews the imminent future of nutrient-stimulated hormone-based anti-obesity therapeutics.

Original language	English (US)
Pages (from-to)	125-139
Number of pages	15
Journal	Annual review of medicine
Volume	74
DOIs	https://doi.org/10.1146/annurev-med-043021-014919
State	Published - Jan 27 2023

Keywords

GLP-1 receptor agonists
NuSH-based therapies
antiobesity medications
dual receptor agonists
nutrient-stimulated hormone-based therapies
triple receptor agonists

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1146/annurev-med-043021-014919

Cite this

@article{dc69d47fc78a4fa99f7b34f3ef92ef66,

title = "New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics",

abstract = "Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of nascent hormone-based obesity therapeutics. With the understanding of the neurobiology of obesity rapidly expanding, these emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 RAs herald a new era of targeted, mechanism-based treatment of obesity. This article reviews GLP-1 RAs in the treatment of obesity and previews the imminent future of nutrient-stimulated hormone-based anti-obesity therapeutics.",

keywords = "GLP-1 receptor agonists, NuSH-based therapies, antiobesity medications, dual receptor agonists, nutrient-stimulated hormone-based therapies, triple receptor agonists",

author = "Jastreboff, {Ania M.} and Kushner, {Robert F.}",

year = "2023",

month = jan,

day = "27",

doi = "10.1146/annurev-med-043021-014919",

language = "English (US)",

volume = "74",

pages = "125--139",

journal = "Annual review of medicine",

issn = "0066-4219",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - New Frontiers in Obesity Treatment

T2 - GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

AU - Jastreboff, Ania M.

AU - Kushner, Robert F.

PY - 2023/1/27

Y1 - 2023/1/27

N2 - Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of nascent hormone-based obesity therapeutics. With the understanding of the neurobiology of obesity rapidly expanding, these emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 RAs herald a new era of targeted, mechanism-based treatment of obesity. This article reviews GLP-1 RAs in the treatment of obesity and previews the imminent future of nutrient-stimulated hormone-based anti-obesity therapeutics.

AB - Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of nascent hormone-based obesity therapeutics. With the understanding of the neurobiology of obesity rapidly expanding, these emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 RAs herald a new era of targeted, mechanism-based treatment of obesity. This article reviews GLP-1 RAs in the treatment of obesity and previews the imminent future of nutrient-stimulated hormone-based anti-obesity therapeutics.

KW - GLP-1 receptor agonists

KW - NuSH-based therapies

KW - antiobesity medications

KW - dual receptor agonists

KW - nutrient-stimulated hormone-based therapies

KW - triple receptor agonists

UR - http://www.scopus.com/inward/record.url?scp=85147094737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147094737&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-043021-014919

DO - 10.1146/annurev-med-043021-014919

M3 - Review article

C2 - 36706749

AN - SCOPUS:85147094737

SN - 0066-4219

VL - 74

SP - 125

EP - 139

JO - Annual review of medicine

JF - Annual review of medicine

ER -

New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this